883 results match your criteria daratumumab

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.

Drugs 2021 Apr 19. Epub 2021 Apr 19.

Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

The plasma cell neoplasm multiple myeloma (MM) is currently considered incurable. However, significant advances in treatment options over the past 20 years have led to unprecedented response rates to initial therapy as well as prolonged survival rates. Induction regimens have evolved from alkylator-based therapies to those consisting of immunomodulatory drugs and proteasome inhibitors. Read More

View Article and Full-Text PDF

Retrospective review of accelerated daratumumab administration.

J Oncol Pharm Pract 2021 Apr 17:10781552211009967. Epub 2021 Apr 17.

Pharmacy Department, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA.

Daratumumab is an anti-CD38 monoclonal antibody approved for multiple myeloma. The initial infusion is administered over a median of 7.5 hours with subsequent infusions given over 3 to 4 hours. Read More

View Article and Full-Text PDF

Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.

Ann Hematol 2021 Apr 16. Epub 2021 Apr 16.

Department of Hematology, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa, Chiba, 277-8577, Japan.

View Article and Full-Text PDF

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.

JAMA Oncol 2021 Apr 15. Epub 2021 Apr 15.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Importance: Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and autologous hemopoietic cell transplant was assessed. Here, we examine the addition of daratumumab to the second-generation proteasome inhibitor-based, 3-drug combination of carfilzomib, lenalidomide, and dexamethasone.

Objective: To assess the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant. Read More

View Article and Full-Text PDF

A Case of Presyncope and Bradycardia With Daratumumab Infusion.

Am J Ther 2021 Apr 7. Epub 2021 Apr 7.

Department of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY Department of Hematology/Oncology, Syracuse VA Medical Center, Syracuse, NY.

View Article and Full-Text PDF

Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.

Clin Infect Dis 2021 Apr 13. Epub 2021 Apr 13.

Division of gastroenterology and hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

The risk of reactivation of resolved HBV in HBsAg-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. Read More

View Article and Full-Text PDF

Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a analysis of phase 3 clinical trials.

Leuk Lymphoma 2021 Apr 9:1-8. Epub 2021 Apr 9.

Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.

It is unknown if daratumumab could affect venous thromboembolism (VTE) risks in patients with multiple myeloma (MM). In this study, individual participant data from three trials comparing daratumumab (DARA) and non-DARA regimens, the CASTOR, PULLOX and MAIA trial, were pooled into two groups. A total of 896 and 899 patients received DARA and non-DARA regimens, respectively. Read More

View Article and Full-Text PDF

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.

Front Immunol 2021 22;12:645478. Epub 2021 Mar 22.

Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by multiple cellular and molecular dysfunctions of the innate and adaptive immunity. Cytotoxic function of NK cells is compromised in patients with SLE. Herein, we characterized the phenotypic alterations of SLE NK cells in a comprehensive manner to further delineate the mechanisms underlying the cytotoxic dysfunction of SLE NK cells and identify novel potential therapeutic targets. Read More

View Article and Full-Text PDF

Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.

BMJ Case Rep 2021 Apr 7;14(4). Epub 2021 Apr 7.

Department of Haematology, Metro South Hospital and Health Service, Woolloongabba, Queensland, Australia.

We report a case of progressive light-chain amyloidosis (otherwise known as AL amyloidosis) with acquired factor X (aFX) deficiency with a complete haematological response and rapid normalisation of FX levels following daratumumab monotherapy. To our knowledge, this is the first case report documenting successful treatment with daratumumab of aFX deficiency secondary to AL amyloidosis. The patient responded well to this therapy, with excellent symptomatic and quality of life improvements as well as a reduction in bleeding manifestations. Read More

View Article and Full-Text PDF

Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.

Br J Haematol 2021 Apr 6. Epub 2021 Apr 6.

Janssen Global Services, Raritan, NJ, USA.

In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone (Rd) alone. Here, we present patient-reported outcomes (PROs) from POLLUX, assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaires. Changes from baseline are presented as least-squares mean changes with 95% confidence intervals (CIs) derived from a mixed-effects model. Read More

View Article and Full-Text PDF

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

J Fungi (Basel) 2021 Mar 5;7(3). Epub 2021 Mar 5.

Pediatric and Adolescent Hematology-Oncology Unit, 2nd Department of Pediatrics, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece.

Since 1985 when the first agent targeting antigens on the surface of lymphocytes was approved (muromonab-CD3), a multitude of such therapies have been used in children with hematologic malignancies. A detailed literature review until January 2021 was conducted regarding pediatric patient populations treated with agents that target CD2 (alefacept), CD3 (bispecific T-cell engager [BiTE] blinatumomab), CD19 (denintuzumab mafodotin, B43, BiTEs blinatumomab and DT2219ARL, the immunotoxin combotox, and chimeric antigen receptor [CAR] T-cell therapies tisagenlecleucel and axicabtagene ciloleucel), CD20 (rituximab and biosimilars, Y-ibritumomab tiuxetan, ofatumumab, and obinutuzumab), CD22 (epratuzumab, inotuzumab ozogamicin, moxetumomab pasudotox, BiTE DT2219ARL, and the immunotoxin combotox), CD25 (basiliximab and inolimomab), CD30 (brentuximab vedotin and iratumumab), CD33 (gemtuzumab ozogamicin), CD38 (daratumumab and isatuximab), CD52 (alemtuzumab), CD66b (Y-labelled BW 250/183), CD248 (ontuxizumab) and immune checkpoint inhibitors against CTLA-4 (CD152; abatacept, ipilimumab and tremelimumab) or with PD-1/PD-L1 blockade (CD279/CD274; atezolizumab, avelumab, camrelizumab, durvalumab, nivolumab and pembrolizumab). The aim of this narrative review is to describe treatment-related invasive fungal diseases (IFDs) of each category of agents. Read More

View Article and Full-Text PDF

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Cells 2021 Mar 4;10(3). Epub 2021 Mar 4.

Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", 27100 Pavia, Italy.

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. Due to the production of amyloidogenic, misfolded LC, AL PCs display peculiar biologic features. The small, indolent plasma cell clone is an ideal target for anti-CD38 immunotherapy. Read More

View Article and Full-Text PDF

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.

Cancers (Basel) 2021 Mar 29;13(7). Epub 2021 Mar 29.

II Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, 20251 Hamburg, Germany.

Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. Read More

View Article and Full-Text PDF

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab.

Torben Plesner

J Clin Med 2021 Mar 2;10(5). Epub 2021 Mar 2.

Department of Hematology, Vejle Hospital, Institute of Regional Health Science, University of Southern Denmark, Beriderbakken 4 DK, 7100 Vejle, Denmark.

A search of the scientific literature for and gives more than 600 results (January 2021), which reflects the interest and activity around this antibody, an interest that was also reflected by the assignment of breakthrough designation for Daratumumab as a treatment for multiple myeloma by FDA in 2013. The high expectations have been supported and met due to a very active clinical development program, and our insight into Daratumumab's modes of action have been expanded by a concomitant, systematic activity of translational research. The scope of this article is to point to some areas where the outcome of treatment with Daratumumab for multiple myeloma may be improved with a focus on areas such as when to initiate treatment with Daratumumab, the use of supportive treatment, duration of therapy and some general thoughts about anti-myeloma treatment as a two-step process involving initial de-bulking followed by reprogramming of the host's immune system and immune-mediated control of myeloma. Read More

View Article and Full-Text PDF

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation.

Ther Adv Hematol 2021 28;12:2040620721989578. Epub 2021 Jan 28.

Department of Hematology and Hematology Research Laboratory, West China Hospital, Sichuan University, Guoxue Alley 37, Chengdu 610041, China.

Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy. Novel therapeutics are needed for PCL, and daratumumab may play role. Read More

View Article and Full-Text PDF
January 2021

Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.

Clin Lymphoma Myeloma Leuk 2021 Mar 4. Epub 2021 Mar 4.

Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.

Introduction: Daratumumab is an anti-CD38 monoclonal antibody widely used for treating patients with newly diagnosed or relapsed/refractory multiple myeloma. The subcutaneous formulation of daratumumab was developed with the purpose of minimizing the treatment burden (to patients and health care system) associated with intravenous daratumumab. Given its recent approval, there is a knowledge gap regarding the best practices that should be instituted for safe administration of subcutaneous daratumumab. Read More

View Article and Full-Text PDF

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.

JAMA Netw Open 2021 Mar 1;4(3):e213497. Epub 2021 Mar 1.

Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Importance: Although the number of treatments for elderly patients with non-transplant-eligible (NTE) multiple myeloma (MM) has increased substantially, evidence is lacking on the clinical effectiveness and cost-effectiveness of novel treatment sequences.

Objective: To determine the optimal sequence of treatment for patients with NTE MM from the perspective of the patient, physician, and society.

Design, Setting, And Participants: Using data from a Dutch observational registry, this economic evaluation combined evidence from network meta-analyses in a patient-level simulation model and modeled time-to-event and types of events from a hospital perspective with a lifetime horizon. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.

Adv Ther 2021 Mar 26. Epub 2021 Mar 26.

Department of Pharmacy, The Second Xiangya Hospital of Central South University, No.139 Renmin Middle Road, Changsha, 410011, Hunan, China.

Introduction: The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China. In the present study, we evaluated the cost-effectiveness of D-VMP versus VMP for patients with newly diagnosed MM in China.

Methods: A Markov model was used to estimate the cost-effectiveness of frontline D-VMP versus VMP for MM. Read More

View Article and Full-Text PDF

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy.

Asian J Transfus Sci 2020 Jul-Dec;14(2):200-202. Epub 2020 Dec 19.

Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Saint Peter's University Hospital, New Brunswick, New Jersey, USA.

CD38 is a disulfide-linked molecule present on red blood cells (RBCs) and daratumumab; an anti-CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. It also binds to the RBC along with the plasma cells in concern, creating a menace in the immunohematology workups and requires the use of dithiothreitol-treated cells to rule out its interference. Appropriate and timely communication with the clinicians about the patient history goes a long way in solving complex looking immunohematology workups. Read More

View Article and Full-Text PDF
December 2020

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.

Front Oncol 2021 5;11:624405. Epub 2021 Mar 5.

Division of Hematology, University Hospital Policlinico Vittorio Emanuele, Catania, Italy.

Background: The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multicentric study was designed to evaluate feasibility, tolerability, and efficacy of daratumumab in monotherapy in RRMM.

Methods: This study included 44 consecutive RRMM patients that underwent daratumumab monotherapy after a median number of four prior therapies (range 2-9). Read More

View Article and Full-Text PDF

MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.

BMJ Open 2021 Mar 24;11(3):e046225. Epub 2021 Mar 24.

Centre for Myeloma Research, Institute of Cancer Research, London, UK

Introduction: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which confer a significantly poorer prognosis, generally termed high-risk (HR) MM. It is important to diagnose these genetic changes early and identify more effective first-line treatment options for these patients. Read More

View Article and Full-Text PDF

Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico.

Arch Med Res 2021 Mar 6. Epub 2021 Mar 6.

Centro de Hematología y Medicina Interna de Puebla, Puebla México.

Background: Despite novel therapies, multiple myeloma (MM) remains an incurable malignancy, daratumumab (DARA) being a major game changer, may be a good option for treatment.

Aimed Of The Study: To assess the prescription patterns of DARA in patients with MM in Mexico.

Methods: 47 patients with MM were analyzed in 13 different hospitals in Mexico. Read More

View Article and Full-Text PDF

Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.

Br J Haematol 2021 Mar 21. Epub 2021 Mar 21.

Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa-Shi, Chiba, Japan.

View Article and Full-Text PDF

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.

Front Immunol 2021 5;12:632399. Epub 2021 Mar 5.

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Immunomodulatory drugs (IMiDs) are effective treatments for patients with multiple myeloma. IMiDs have pleotropic effects including targeting the myeloma cells directly, and improving the anti-myeloma immune response. In the absence of myeloma cells, lenalidomide and pomalidomide induce CD4 T cell secretion of IL-2 and indirect activation of Natural Killer (NK) cells. Read More

View Article and Full-Text PDF

Antibody treatment in multiple myeloma.

Clin Adv Hematol Oncol 2021 Mar;19(3):166-174

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.

Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved. Read More

View Article and Full-Text PDF

Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.

Expert Rev Hematol 2021 Mar 31:1-12. Epub 2021 Mar 31.

Department of Hematology, University of Leuven and Leuven Cancer Institute, Leuven, Belgium.

: Impressive therapeutic progress is being made in the management of multiple myeloma (MM). his progress is related to the introduction of several new classes of therapeutic agents including proteasome inhibitors, immunomodulatory drugs (IMiDs) and monoclonal antibodies (MoAbs).: In this manuscript, the role of the IMiDs thalidomide and lenalidomide in the management of newly diagnosed MM is discussed. Read More

View Article and Full-Text PDF

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.

Front Immunol 2021 1;12:649441. Epub 2021 Mar 1.

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Daratumumab is a monoclonal antibody directed against the transmembrane glycoprotein CD38 expressed on plasma cells and lymphoplasmocytes, with a proven efficacy in multiple myeloma. Here we show its clinical efficacy in a patient with cold agglutinin disease (CAD) relapsed after multiple lines of therapy. CAD is caused by cold reactive autoantibodies that induce complement mediated hemolysis and peripheral circulatory symptoms. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.

Front Pharmacol 2021 1;12:608685. Epub 2021 Mar 1.

Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, China.

To evaluate the cost-effectiveness of adding daratumumab to bortezomib, melphalan, and prednisone for transplant-ineligible newly diagnosed multiple myeloma patients. A three-state Markov model was developed from the perspective of US payers to simulate the disease development of patient's life time for daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) and bortezomib, melphalan, and prednisone (VMP) regimens. The primary outputs were total costs, expected life-years (LYs), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Read More

View Article and Full-Text PDF